Amneal Pharmaceuticals, Inc. (AMRX)

Generic and specialty drug maker, mostly in India. Read October 19, 2026 from the annual report for the period ending December 31, 2025, filed February 27, 2026. Ranked 55 of the 104 Healthcare companies read so far, by the share within reach now.

A generics maker whose filing counts 8,500 Amneal Employees, 2,500 in the U.S., and 200 at its AvKARE distributor, so pharmaceutical manufacturing carries nearly all and the counted distributor keeps its own share.

The figures on this page come from the company's own annual report and from BLS staffing patterns for its industries, never from a roster. They are estimates with a stated method. Nothing here says what the company will do: within reach is not a forecast of jobs lost or of savings.

What follows from the reading

Share of working time within reach of AI, on the long-run pace at four in five: 19% now, 34% at the end of 2027, 41% at the end of 2028, 44% at the end of 2030. By the patterns, the work is about 44% desk work, 14% people work and 41% body work. These are the site's industry estimates weighted by the shares below: estimates with a stated method and range, not a forecast of what the company will do. By the same patterns, at the end of 2028 about 57% of the working time stays with people (conversation, in-person and hands-on work), 36% becomes checking a model's work and 4% could be handed over with lighter checks, from the industries' own figures, not the company's roles.

Headcount

8,700 employees as of December 31, 2025 (sum of stated parts). Derived from stated parts, said so: nearly 2,500 of the Amneal Employees are in the U.S. and over 6,000 outside it, primarily in India and Ireland; AvKARE's approximately 200 are in the U.S., so about 2,700 of 8,700.

The filing: “As of December 31, 2025, we had over 8,500 employees ("Amneal Employees"), excluding approximately 200 employees in our AvKARE segment.”

The workforce as industry patterns

What the filing says about the workforce: Over 8,500 Amneal Employees as of December 31, 2025, nearly 2,500 in the U.S. and over 6,000 outside it, primarily in India and Ireland, plus approximately 200 in the AvKARE segment; about 2,000 hired in 2025; total turnover 17.9%; 70% completed a talent profile on its AI-enabled career platform.

Companies read with the same leading pattern

Other companies whose largest staffing pattern is also Pharmaceutical and Medicine Manufacturing, largest first, each read from its own annual report. Within reach now and at the end of 2028, long-run pace, four in five.

• Johnson & Johnson (JNJ, 140,800 employees)19% now, 39% by 2028
• Thermo Fisher Scientific Inc. (TMO, 125,000 employees)20% now, 49% by 2028
• Merck & Co., Inc. (MRK, 75,000 employees)19% now, 41% by 2028
• Pfizer Inc. (PFE, 75,000 employees)19% now, 41% by 2028
• AbbVie Inc. (ABBV, 57,000 employees)19% now, 41% by 2028
• Eli Lilly and Company (LLY, 50,000 employees)19% now, 41% by 2028
• Bristol-Myers Squibb Company (BMY, 32,500 employees)19% now, 41% by 2028
• Amgen Inc. (AMGN, 31,500 employees)19% now, 41% by 2028

What the filing says about AI

17 sentences in the filing name AI. The filing names My Amneal Career, an AI-enabled talent platform for skills and talent visibility that 70% of global employees used, and lists AI among the risks and competitive factors it faces.

• “Summary of Material Risks Risks and uncertainties that make an investment in the Company speculative or risky or that could cause our actual results to differ materially from the forward-looking statements contained in this Annual Report on Form 10-K, include, but are not limited to: our ability to successfully develop, license, acquire and commercialize new products on a timely basis; the comp...”
• “We also enhanced our talent management capabilities via My Amneal Career, an AI-enabled platform focused on expanding organization-wide skills and talent visibility, supported by leadership engagement and broad employee participation with 70% of global employees completing their My Amneal Career Talent Profile.”
• “The principal competitive factors in the pharmaceutical market include: introduction of other generic drug manufacturers' products in direct competition with our generic drug products; introduction of authorized generic drug products in direct competition with our generic or branded products, particularly during exclusivity periods; the ability of generic drug product competitors to quickly ent...”
• “Furthermore, we may not be able to (i) differentiate our products, (ii) successfully develop or introduce new products, on a timely basis or at all, that are less costly, (iii) integrate new systems or technology, such as AI, as quickly or successfully, or (iv) offer customers payment and other commercial terms as favorable as those offered by our competitors.”
• “Our systems may be susceptible to intentional or accidental physical damage to the infrastructure maintained by us or by third parties, including as a result of extreme weather events, such as fires, floods, hurricanes, or tornadoes or as the result of the use of AI or other new technologies.”

Its annual reports, year by year

Sentences naming AI in each annual report, counted by one rule, beside the median report in the Index that year. Each count links its filing. Every company, by year and sector

• Fiscal 20213median 0
• Fiscal 20220median 0
• Fiscal 202314median 1
• Fiscal 202416median 4
• Fiscal 202517median 10

Headcount by filing year

As reported in each year's annual report, with the filing. A year marked not read had no figure the reading could take from the report's text.

Limits of this reading

• The count sums the over 8,500 Amneal Employees and the approximately 200 AvKARE employees the filing states apart (rule 2).
• The U.S. share is derived from the stated U.S. and non-U.S. counts, not stated as a share.

Source: the company's annual report on EDGAR, accession 0001723128-26-000011, the filing. Read by Claude Fable 5.1 under rubric version 1, by the method. A company can write to info@stratussc.com to have its reading checked against its filing.